POL5551, as a peptidic CXCR4 antagonist, enhanced the susceptibility of tumor cells to anoikis by mobilizing tumor cells into surrounding blood and significantly reduced distant metastasis in TNBC in situ model [294]. The gene discussed is CXCR4; the disease is neoplasm.